IFRA's upcoming amendment "very light"
This article was originally published in The Rose Sheet
Executive Summary
The International Fragrance Association's 45 Amendment to its Code of Practice, introduced this year, "will hardly affect the palettes of perfumers," states IFRA Director General Jean-Pierre Houri in a June 2 release. Rumors that the upcoming version of the amendment includes new policies on furocoumarins or methyleugenol (an essential component of the smell of roses) are simply "wrong," he says, noting there are only seven changes to the amendment overall. "Previous years have seen quite heavy amendments due to the change over to our new Quantitative Risk Assessment approach," Houri says. "However, this is nearly complete and is reflected in this year's very light amendment." IFRA's Research Institute for Fragrance Materials has bumped heads with industry representatives and European scientific authorities previously regarding its increasingly refined QRA (1"The Rose Sheet" Oct. 27, 2008)
You may also be interested in...
IFRA updates industry code
International Fragrance Association's 45 amendment to its Code of Practice contains seven changes: new standards for dimethylcyclohex-3-ene-1-carbaldehyde (mixed isomers), alpha-methyl-1,2-benzodioxole-5-propionaldehyde (MMDHCA) and 3-phenylbutanal; one revised standard for verbena absolute (Lippia citriodora Kunth.); one revised standard for 2,2-dimethyl-3-(3-tolyl)propan-1-ol (majantol); one new specification standard for musk ketone; and one new prohibition on quinoline, an aromatic organic compound. As expected, the amendment was "light" compared with previous years, as organization's changeover to dermal sensitization Quantitative Risk Assessment approach has been completed (1"The Rose Sheet" June 7, 2010, In Brief)
RIFM, European Scientists Work To Iron Out Differences On QRA Methodology
The Research Institute for Fragrance Materials is in talks with industry representatives and European scientific authorities regarding its quantitative risk assessment (QRA) approach to fragrance sensitization, which has been received with varying degrees of enthusiasm
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.